Artivion (NYSE:AORT) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Artivion (NYSE:AORT) posted its quarterly earnings results on Thursday. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02, Zacks reports. The business had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm’s revenue for the quarter was up 18.9% on a year-over-year basis. Artivion updated its FY 2025 guidance to EPS.

Artivion Stock Performance

Shares of AORT opened at $44.82 on Friday. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -106.72 and a beta of 1.65. Artivion has a 12 month low of $21.97 and a 12 month high of $47.69. The firm has a fifty day simple moving average of $42.44 and a 200 day simple moving average of $35.40. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Analysts Set New Price Targets

Several equities analysts have weighed in on AORT shares. Oppenheimer reissued an “outperform” rating and issued a $50.00 target price on shares of Artivion in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. JMP Securities lifted their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Stifel Nicolaus increased their price target on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Finally, Needham & Company LLC lifted their price objective on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Insider Buying and Selling

In other Artivion news, SVP Marshall S. Stanton sold 18,200 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the sale, the senior vice president owned 64,200 shares in the company, valued at $2,826,084. This represents a 22.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James P. Mackin sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the transaction, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,858 shares of company stock worth $3,250,129 over the last 90 days. 7.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Artivion

A number of hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its holdings in Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares during the period. AQR Capital Management LLC raised its position in shares of Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after buying an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after buying an additional 1,032 shares in the last quarter. Creative Planning increased its stake in Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after acquiring an additional 753 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.